Rheumatoid arthritis runs a variable course with frequent exacerbations and remissions. Clinical and laboratory evidence of disease activity relate to progressive joint damage. -3 Although it is accepted that slow acting antirheumatic drugs (SAARDs) improve laboratory and clinical features of disease, it is not accepted that they may decrease the rate of radiological progression.45 We have previously demonstrated that a group of patients with RA receiving SAARDs showed progressive radiological damage throughout the first 12 months of therapy but that a subgroup who achieved a good response to therapy at six months, maintained at 12 months, had less deterioration.6 7 SAARD therapy is potentially toxic, so the risk-benefit ratio has to be estimated by the clinician for each 
